Article in Science translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed.
bioRxiv : the preprint server for biology · 2026
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors.
Talia GreensteinDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, USA.ORCID 0000-0002-2710-602X
Laura E ViaTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD, USA.ORCID 0000-0001-6074-9521
Mariana Pereira MoraesDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, USA.ORCID 0009-0004-0962-2620
Danielle M WeinerTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD, USA.ORCID 0000-0002-4659-7426
Emmanuel K DayaoTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD, USA.
April M WalkerTuberculosis Imaging Program, Division of Intramural Research, NIAID, NIH, Bethesda, MD, USA.
Joel D FleegleTuberculosis Imaging Program, Division of Intramural Research, NIAID, NIH, Bethesda, MD, USA.
Felipe GomezTuberculosis Imaging Program, Division of Intramural Research, NIAID, NIH, Bethesda, MD, USA.
Katelyn M RepoliTuberculosis Imaging Program, Division of Intramural Research, NIAID, NIH, Bethesda, MD, USA.ORCID 0009-0000-1218-2508
Michael J WoodcockTuberculosis Imaging Program, Division of Intramural Research, NIAID, NIH, Bethesda, MD, USA.
Helena I M BoshoffTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD, USA.ORCID 0000-0002-4333-206X
Oluwaseun EgbelowoDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-5636-4642
Kamunkhwala GausiDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-9002-8087
Paolo DentiDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0001-7494-079X
Firat KayaCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.ORCID 0000-0001-8655-2065
Matthew ZimmermanCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.ORCID 0000-0002-4390-3555
Eric L MillerDepartment of Electrical and Computer Engineering, Tufts University School of Engineering, Medford, MA, USA.ORCID 0000-0002-3156-6002
Véronique A DartoisCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.ORCID 0000-0001-9470-5009
Clifton E BarryTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD, USA.ORCID 0000-0002-2927-270X
Bree B AldridgeDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, USA.ORCID 0000-0003-2236-1424
Funding
Lesion-centric optimization of multidrug therapies for tuberculosisR01AI150684 · NIAID · TUFTS UNIVERSITY BOSTON · PI ALDRIDGE, BREE BEARDSLEY, KIRSCHNER, DENISE E · 2020 to 2024
$4.2M
Gates Foundation INV-010245Gates Foundation INV-027276NIAID NIH HHS R01 AI150684
6 · The paper itself
Abstract
Early bactericidal activity and time to sputum conversion are well-established study end points in both preclinical animal models and clinical trials for testing drug regimens for pulmonary tuberculosis (TB). The development and optimization of treatment-shortening drug regimens for TB have been challenged by disparities between these study end points and nonrelapsing cure. We hypothesized that using lung lesions measured by 2-deoxy-2-[
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
PET/CT imaging of tuberculosis lung lesions in marmosets treated with different drug regimens aligns with human clinical outcomes. · full record | Socratic